Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, et al.; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015 Aug;11(8):471-82. Erratum in: Nat Rev Neurol. 2015 Aug;11(8):483. [Pubmed]
Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017 Apr 1;389(10076):1336-46. [Pubmed]
Uhlenbrock D, Seidel D, Gehlen W, Beyer HK, Haan J, Dickmann E, et al. MR imaging in multiple sclerosis: comparison with clinical, CSF, and visual evoked potential findings. AJNR Am J Neuroradiol. 1988 Jan-Feb;9(1):59-67. [Pubmed]
Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012 Feb;11(2):157-69. [Pubmed]
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7. [Pubmed]
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 Dec;58(6):840-6. [Pubmed]
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. [Pubmed]
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. [Pubmed]
Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler. 2009 Jul;15(7):848-53. [Pubmed]
Sormani MP, Río J, Tintorè M, Signori A, Li D, Cornelisse P, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013 Apr;19(5):605-12. [Pubmed]
Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, et al.; MAGNIMS study group. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018 Apr;14(4):199-213. Erratum in: Nat Rev Neurol. 2018 Mar 20;14 (4):213. [Pubmed]
Solomon AJ, Pettigrew R, Naismith RT, Chahin S, Krieger S, Weinshenker B. Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria. Mult Scler. 2021 Feb;27(2):250-8. [Pubmed]
Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019 May;15(5):287-300. [Pubmed]
Masdeu JC, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P. Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology. 2000 Apr 11;54(7):1427-33. [Pubmed]
Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, et al.; Magnetic Resonance Imaging in Multiple Sclerosis study group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021 Aug;20(8):653-70. [Pubmed]
Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacManus DG, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology. 1993 Dec;43(12):2632-7. [Pubmed]
Friedman DP, Tartaglino LM, Fisher AR, Flanders AE. MR imaging in the diagnosis of intramedullary spinal cord diseases that involve specific neural pathways or vascular territories. AJR Am J Roentgenol. 1995 Sep;165(3):515-23. [Pubmed]
Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, et al. Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol. 2016 Mar;37(3):394-401. [Pubmed]
Philpott C, Brotchie P. Comparison of MRI sequences for evaluation of multiple sclerosis of the cervical spinal cord at 3 T. Eur J Radiol. 2011 Dec;80(3):780-5. [Pubmed]
Bot JC, Barkhof F, Lycklama à Nijeholt GJ, Bergers E, Polman CH, Adèr HJ, Castelijns JA. Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis. Eur Radiol. 2000;10(5):753-8. [Pubmed]
Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002 Jun;15(3):239-45. [Pubmed]
Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler. 2010 Feb;16(2):156-65. [Pubmed]
Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008 Jun;65(6):727-32. [Pubmed]
Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008 Mar;131(Pt 3):808-17. [Pubmed]
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015 Jul;21(8):1013-24. [Pubmed]
Filippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 1995 Feb;45(2):255-60. [Pubmed]
Tintoré M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015 Jul;138(Pt 7):1863-74. [Pubmed]
Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004 Feb;61(2):217-21. [Pubmed]
Sormani MP, De Stefano N. Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol. 2013 Sep;9(9):504-12. [Pubmed]
Diebold M, Altersberger V, Décard BF, Kappos L, Derfuss T, Lorscheider J. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult Scler. 2019 Oct;25(12):1682-5. [Pubmed]
Nakahara J, Tomaske L, Kume K, Takata T, Kamada M, Deguchi K, et al. Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased? Neurol Neuroimmunol Neuroinflamm. 2019 Apr 10;6(3):e559. [Pubmed]
Giovannoni G. De Novo PML on ocrelizumab. Oct 16, 2019. Disponible en: [Enlace]
Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y, et al. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1138-45. [Pubmed]
McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):117-25. [Pubmed]
Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S; Italian PML Group. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):261-7. [Pubmed]
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016 Sep;9 Suppl 1:S5-S48. [Pubmed]
De Stefano N, Stromillo ML, Giorgio A, Bartolozzi ML, Battaglini M, Baldini M, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):93-9. [Pubmed]
Horakova D, Dwyer MG, Havrdova E, Cox JL, Dolezal O, Bergsland N, et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci. 2009 Jul 15;282(1-2):112-9. [Pubmed]
Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008 Sep;64(3):247-54. Erratum in: Ann Neurol. 2009 Feb;65(2):232. [Pubmed]
Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008 Sep;64(3):255-65. [Pubmed]
Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler. 2011 Sep;17(9):1098-106. [Pubmed]
Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci. 2009 Jul 15;282(1-2):106-11. [Pubmed]
Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Kilidireas C, Voumvourakis K. The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. PLoS One. 2015 Mar 10;10(3):e0116511. [Pubmed]
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al.; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402-15. [Pubmed]
CAMMS223 Trial Investigators; Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 Oct 23;359(17):1786-801. [Pubmed]
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011 Apr;10(4):338-48. [Pubmed]
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al.; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829-39. [Pubmed]
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al.; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-34. [Pubmed]
Radue EW, Sprenger T, Gaetano L, Mueller-Lenke N, Wuerfel J, Wolinsky JS, et al. Teriflunomide slows brain volume loss in relapsing MS: a SIENA analysis of the TEMSO MRI dataset. Mult Scler. 2015;21(S11):782.
Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al.; SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019 Nov;18(11):1009-20. [Pubmed]
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al.; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-57. [Pubmed]
Steenwijk MD, Geurts JJ, Daams M, Tijms BM, Wink AM, Balk LJ, et al. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain. 2016 Jan;139(Pt 1):115-26. [Pubmed]
Azevedo CJ, Cen SY, Khadka S, Liu S, Kornak J, Shi Y, et al. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol. 2018 Feb;83(2):223-34. [Pubmed]
Lansley J, Mataix-Cols D, Grau M, Radua J, Sastre-Garriga J. Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. Neurosci Biobehav Rev. 2013 Jun;37(5):819-30. [Pubmed]
Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014 Oct;76(4):568-80. [Pubmed]
Rovira A, Alonso J. 1H magnetic resonance spectroscopy in multiple sclerosis and related disorders. Neuroimaging Clin N Am. 2013 Aug;23(3):459-74. [Pubmed]
Horsfield MA, Barker GJ, Barkhof F, Miller DH, Thompson AJ, Filippi M. Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. J Magn Reson Imaging. 2003 Apr;17(4):389-97. [Pubmed]
Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage. 2012 Sep;62(3):1593-9. [Pubmed]
Haacke EM, Makki M, Ge Y, Maheshwari M, Sehgal V, Hu J, et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging. 2009 Mar;29(3):537-44. [Pubmed]
Lassmann H. Mechanisms of white matter damage in multiple sclerosis. Glia. 2014 Nov;62(11):1816-30. [Pubmed]
Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, et al.; NAIMS Cooperative. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016 Dec;12(12):714-22. [Pubmed]
Sati P, George IC, Shea CD, Gaitán MI, Reich DS. FLAIR*: a combined MR contrast technique for visualizing white matter lesions and parenchymal veins. Radiology. 2012 Dec;265(3):926-32. [Pubmed]
Sbardella E, Tona F, Petsas N, Pantano P. DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications. Mult Scler Int. 2013;2013:671730. [Pubmed]
Elliott C, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler. 2019 Dec;25(14):1915-25. [Pubmed]
Popescu BF, Frischer JM, Webb SM, Tham M, Adiele RC, Robinson CA, et al. Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions. Acta Neuropathol. 2017 Jul;134(1):45-64. [Pubmed]
Blindenbacher N, Brunner E, Asseyer S, Scheel M, Siebert N, Rasche L, et al. Evaluation of the 'ring sign' and the 'core sign' as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis. Mult Scler J Exp Transl Clin. 2020 Mar 30;6(1):2055217320915480. [Pubmed]
Zivadinov R, Ramasamy DP, Vaneckova M, Gandhi S, Chandra A, Hagemeier J, et al. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Mult Scler. 2017 Sep;23(10):1336-45. [Pubmed]
Absinta M, Vuolo L, Rao A, Nair G, Sati P, Cortese IC, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015 Jul 7;85(1):18-28. [Pubmed]
Bodini B, Tonietto M, Airas L, Stankoff B. Positron emission tomography in multiple sclerosis - straight to the target. Nat Rev Neurol. 2021 Nov;17(11):663-75. [Pubmed]
Högel H, Rissanen E, Vuorimaa A, Airas L. Positron emission tomography imaging in evaluation of MS pathology in vivo. Mult Scler. 2018 Oct;24(11):1399-412. [Pubmed]
Parisi V, Manni G, Spadaro M, Colacino G, Restuccia R, Marchi S, Bucci MG, Pierelli F. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2520-7. [Pubmed]
Kuchling J, Paul F. Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Front Neurol. 2020 Jun 17;11:450. [Pubmed]
Vidal-Jordana A, Pareto D, Cabello S, Alberich M, Río J, Tintoré M, et al. Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability. Eur J Neurol. 2020 Nov;27(11):2225-32. [Pubmed]
Shi C, Jiang H, Gameiro GR, Hu H, Hernández J, Delgado S, Wang J. Visual Function and Disability Are Associated With Focal Thickness Reduction of the Ganglion Cell-Inner Plexiform Layer in Patients With Multiple Sclerosis. Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1213-23. [Pubmed]
Martínez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, et al.; IMSVISUAL consortium. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016 May;15(6):574-84. [Pubmed]
Siger M, Dziegielewski K, Jasek L, Bieniek M, Nicpan A, Nawrocki J, Selmaj K. Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol. 2008 Oct;255(10):1555-60. [Pubmed]
Paul F, Calabresi PA, Barkhof F, Green AJ, Kardon R, Sastre-Garriga J, et al. Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. Ann Clin Transl Neurol. 2021 Dec;8(12):2235-51. [Pubmed]